La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2021 and Highlights Corporate Progress

2021-11-04

财报并购

Nov. 4, 2021 12:45 UTC La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2021 and Highlights Corporate Progress WALTHAM, Mass.--(BUSINESS WIRE)-- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and nine months ended September 30, 2021 and highlighted corporate progress. Corporate Progress Increased Net Product Sales: For the three and nine months ended September 30, 2021, La Jolla’s net product sales were $11.8 million and $31.5 million, respectively, compared to $9.1 million and $22.5 million, respectively, for the same periods in 2020. La Jolla acquired Tetraphase, which commercialized XERAVA, on July 28, 2020. Net product sales for the three and nine months ended September 30, 2020 excludes XERAVA for the period prior to July 28, 2020. GIAPREZA U.S. Net Product Sales: For the three months ended September 30, 2021, GIAPREZA U.S. net product sales were $8.9 million, up 3% from the three months ended June 30, 2021 and up 24% from the three months ended September 30, 2020. For the nine months ended September 30, 2021, GIAPREZA U.S. net product sales were $24.3 million, up 18% from the same period in 2020. XERAVA U.S. Net Product Sales: For the three months ended September 30, 2021, XERAVA U.S. net product sales were $2.9 million, up 16% from the three months ended June 30, 2021 and up 7% from the three months ended September 30, 2020, including the period prior to the acquisition of Tetraphase. For the nine months ended September 30, 2021, XERAVA U.S. net product sales were $7.2 million, up 22% from the same period in 2020, including the period prior to the acquisition of Tetraphase. Positive Net Cash Provided by Operating Activities: La Jolla’s net cash provided by (used for) operating activities for the three and nine months ended September 30, 2021 was $0.8 million and $25.1 million, respectively, compared to $(9.8) million and $(30.4) million, respectively, for the same periods in 2020. La Jolla’s net cash provided by (used for) operating activities for the three and nine months ended September 30, 2021, excluding upfront net receipts in connection with out-license agreements and commercial supply agreements, payments related to reductions in headcount, and transaction costs associated with the Tetraphase acquisition, was $1.1 million and $1.5 million, respectively, compared to $(5.6) million and $(21.6) million, respectively, for the same periods in 2020. “We are pleased to report that La Jolla had a record quarter for net product sales of both GIAPREZA and XERAVA for the three months ended September 30, 2021, and La Jolla had positive operating cash flow for the third consecutive quarter. These are significant achievements for La Jolla,” said Larry Edwards, President and Chief Executive Officer of La Jolla. “La Jolla continues to focus on growing net product sales of both GIAPREZA and XERAVA and generating positive operating cash flow.” Financial Results For the three and nine months ended September 30, 2021, La Jolla’s total revenue was $13.3 million and $63.5 million, respectively, compared to $9.1 million and $22.5 million, respectively, for the same periods in 2020. La Jolla’s total revenue was comprised of the following: For the three and nine months ended September 30, 2021, La Jolla’s net product sales were $11.8 million and $31.5 million, respectively, compared to $9.1 million and $22.5 million, respectively, for the same periods in 2020. GIAPREZA U.S. net product sales were $8.9 million and $24.3 million for the three and nine months ended September 30, 2021, compared to $7.2 million and $20.6 million, respectively, for the same periods in 2020. XERAVA U.S. net product sales were $2.9 million and $7.2 million for the three and nine months ended September 30, 2021, compared to $1.9 million for the three and nine months ended September 30, 2020. For the three and nine months ended September 30, 2021, La Jolla’s license and other revenue was $1.5 million and $32.0 million, respectively, compared to zero for the same periods in 2020. La Jolla’s net income (loss) for the three and nine months ended September 30, 2021 was $(2.3) million and $15.9 million, or $(0.08) and $0.46 per diluted share, respectively, compared to $(11.8) million and $(35.9) million, or $(0.43) and $(1.32) per diluted share, respectively, for the same periods in 2020. As of September 30, 2021 and December 31, 2020, La Jolla had cash and cash equivalents of $46.8 million and $21.2 million, respectively. La Jolla’s net cash provided by (used for) operating activities for the three and nine months ended September 30, 2021 was $0.8 million and $25.1 million, respectively, compared to $(9.8) million and $(30.4) million, respectively, for the same periods in 2020. La Jolla’s net cash provided by (used for) operating activities for the three and nine months ended September 30, 2021, excluding upfront net receipts in connection with out-license agreements and commercial supply agreements, payments related to reductions in headcount, and transaction costs associated with the Tetraphase acquisition, was $1.1 million and $1.5 million, respectively, compared to $(5.6) million and $(21.6) million, respectively, for the same periods in 2020. The exclusions above are comprised of the following: Upfront net receipts in connection with out-license agreements were zero and $18.4 million for the three and nine months ended September 30, 2021, respectively, and zero for the same periods in 2020. Upfront net receipts in connection with commercial supply agreements were zero and $6.8 million for the three and nine months ended September 30, 2021, and zero for the same periods in 2020. Payments related to reductions in headcount were $0.3 million and $1.6 million for the three and nine months ended September 30, 2021, respectively, and $3.3 million and $7.9 million, respectively, for the same periods in 2020. Payments related to transaction costs associated with the Tetraphase acquisition were zero for the three and nine months ended September 30, 2021, and $0.9 million for the three and nine months ended September 30, 2020. About GIAPREZA GIAPREZA™ (angiotensin II) injection is approved by the U.S. Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. GIAPREZA is approved by the European Commission (EC) for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. GIAPREZA mimics the body’s endogenous angiotensin II peptide, which is central to the renin-angiotensin-aldosterone system, which in turn regulates blood pressure. Prescribing information for GIAPREZA is available at . The European Summary of Product Characteristics is available at . GIAPREZA is marketed in the U.S. by La Jolla Pharmaceutical Company on behalf of La Jolla Pharma, LLC, its wholly owned subsidiary, and is marketed in Europe by PAION Deutschland GmbH on behalf of La Jolla Pharma, LLC. GIAPREZA Important Safety Information Contraindications None. Warnings and Precautions There is a potential for venous and arterial thrombotic and thromboembolic events in patients who receive GIAPREZA. Use concurrent venous thromboembolism (VTE) prophylaxis. Adverse Reactions The most common adverse reactions that were reported in greater than 10% of GIAPREZA-treated patients were thromboembolic events. Drug Interactions Angiotensin converting enzyme (ACE) inhibitors may increase response to GIAPREZA. Angiotensin II receptor blockers (ARBs) may reduce response to GIAPREZA. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. For additional information, please see Full Prescribing Information for the United States and the Summary of Product Characteristics for the European Union. About XERAVA XERAVA™ (eravacycline) for injection is approved by the U.S. Food and Drug Administration (FDA) as a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI) in patients 18 years of age and older. XERAVA is approved by the European Commission (EC) for the treatment of cIAI in adults. Prescribing information for XERAVA is available at . The European Summary of Product Characteristics is available at . XERAVA is marketed in the U.S. by Tetraphase Pharmaceuticals, Inc., a wholly owned subsidiary of La Jolla, and is marketed in Europe by PAION Deutschland GmbH on behalf of Tetraphase Pharmaceuticals, Inc. Everest, the Company’s licensee for mainland China, Taiwan, Hong Kong, Macau, South Korea, Singapore, the Malaysian Federation, the Kingdom of Thailand, the Republic of Indonesia, the Socialist Republic of Vietnam and the Republic of the Philippines, submitted an NDA in China, which was accepted by the China National Medical Products Administration (NMPA) in March 2021. XERAVA Important Safety Information XERAVA is a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. XERAVA is not indicated for the treatment of complicated urinary tract infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of XERAVA and other antibacterial drugs, XERAVA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. XERAVA is contraindicated for use in patients with known hypersensitivity to eravacycline, tetracycline-class antibacterial drugs or to any of the excipients. Life-threatening hypersensitivity (anaphylactic) reactions have been reported with XERAVA. The use of XERAVA during tooth development (last half of pregnancy, infancy and childhood to the age of eight years) may cause permanent discoloration of the teeth (yellow-gray-brown) and enamel hypoplasia. The use of XERAVA during the second and third trimester of pregnancy, infancy and childhood up to the age of eight years may cause reversible inhibition of bone growth. Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents and may range in severity from mild diarrhea to fatal colitis. The most common adverse reactions observed in clinical trials (incidence ≥ 3%) were infusion site reactions, nausea and vomiting. XERAVA is structurally similar to tetracycline-class antibacterial drugs and may have similar adverse reactions. Adverse reactions including photosensitivity, pseudotumor cerebri and anti-anabolic action, which has led to increased blood urea nitrogen, azotemia, acidosis, hyperphosphatemia, pancreatitis and abnormal liver function tests, have been reported for other tetracycline-class antibacterial drugs, and may occur with XERAVA. Discontinue XERAVA if any of these adverse reactions are suspected. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. For additional information, please see Full Prescribing Information for the United States. About La Jolla Pharmaceutical Company La Jolla Pharmaceutical Company is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. GIAPREZA™ (angiotensin II) injection is approved by the FDA as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. XERAVA™ (eravacycline) for injection is approved by the FDA as a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI) in patients 18 years of age and older. For more information, please visit . Forward-looking Statements This press release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. We caution investors that forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and involve substantial risks and uncertainties that could cause the actual outcomes to differ materially from what we currently expect. These risks and uncertainties include, but are not limited to, those associated with: GIAPREZA™ (angiotensin II) and XERAVA™ (eravacycline) sales; operating costs; regulatory actions relating to La Jolla’s products by the U.S. FDA, European Commission, China National Medical Products Administration and/or other regulatory authorities; expected future cash flows of La Jolla, including upfront, milestone, royalty and other payments resulting from La Jolla’s out-license agreements and commercial supply agreements; and other risks and uncertainties identified in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements in this press release apply only as of the date made, and we undertake no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances. LA JOLLA PHARMACEUTICAL COMPANY Condensed Consolidated Balance Sheets (in thousands, except par value and share amounts) September 30, December 31, 2021 2020 (Unaudited) ASSETS Current assets: Cash and cash equivalents $ 46,765 $ 21,221 Accounts receivable, net 8,793 5,834 Inventory, net 6,094 6,013 Prepaid expenses and other current assets 4,263 3,388 Total current assets 65,915 36,456 Goodwill 20,123 20,123 Intangible assets, net 13,709 14,873 Right-of-use lease assets 367 536 Property and equipment, net 140 215 Restricted cash 40 40 Total assets $ 100,294 $ 72,243 LIABILITIES AND SHAREHOLDERS’ DEFICIT Current liabilities: Accounts payable $ 2,314 $ 2,762 Accrued expenses 11,720 6,494 Accrued payroll and related expenses 1,801 2,878 Lease liabilities, current portion 160 204 Total current liabilities 15,995 12,338 Deferred royalty obligation, net 124,487 124,437 Accrued interest expense on deferred royalty obligation, less current portion 23,489 19,111 Lease liabilities, less current portion 208 332 Other noncurrent liabilities 4,523 4,112 Total liabilities 168,702 160,330 Commitments and contingencies Shareholders’ deficit: Common Stock, $0.0001 par value; 100,000,000 shares authorized, 27,518,191 and 27,402,648 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively 3 3 Series C-12 Convertible Preferred Stock, $0.0001 par value; 11,000 shares authorized, 3,906 shares issued and outstanding at September 30, 2021 and December 31, 2020; and liquidation preference of $3,906 at September 30, 2021 and December 31, 2020 3,906 3,906 Additional paid-in capital 988,544 984,756 Accumulated deficit (1,060,861 ) (1,076,752 ) Total shareholders’ deficit (68,408 ) (88,087 ) Total liabilities and shareholders’ deficit $ 100,294 $ 72,243 LA JOLLA PHARMACEUTICAL COMPANY Condensed Consolidated Statements of Operations (Unaudited) (in thousands, except per share amounts) Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 Revenue Net product sales $ 11,781 $ 9,072 $ 31,477 $ 22,468 License and other revenue 1,533 - 32,033 - Total revenue 13,314 9,072 63,510 22,468 Operating expenses Cost of product sales 2,031 2,489 6,918 4,013 Cost of license and other revenue 841 - 4,441 - Selling, general and administrative 8,632 12,493 26,383 29,322 Research and development 1,285 3,617 3,957 21,581 Total operating expenses 12,789 18,599 41,699 54,916 Income (loss) from operations 525 (9,527 ) 21,811 (32,448 ) Other (expense) income Interest expense (2,729 ) (2,526 ) (8,010 ) (7,402 ) Interest income - 12 2 234 Other income—related party - - 2,532 4,085 Other (expense) income (25 ) 281 (395 ) (412 ) Total other (expense) income, net (2,754 ) (2,233 ) (5,871 ) (3,495 ) Income (loss) before income taxes (2,229 ) (11,760 ) 15,940 (35,943 ) Provision for income taxes 31 - 49 - Net income (loss) $ (2,260 ) $ (11,760 ) $ 15,891 $ (35,943 ) Earnings (loss) per share Basic $ (0.08 ) $ (0.43 ) $ 0.58 $ (1.32 ) Diluted $ (0.08 ) $ (0.43 ) $ 0.46 $ (1.32 ) Shares used in computing earnings (loss) per share Basic 27,497 27,368 27,462 27,311 Diluted 27,497 27,368 34,206 27,311 LA JOLLA PHARMACEUTICAL COMPANY Condensed Consolidated Statements of Cash Flows (Unaudited) (in thousands) Nine Months Ended September 30, 2021 2020 Operating activities Net income (loss) $ 15,891 $ (35,943 ) Adjustments to reconcile net income (loss) to net cash provided by (used for) operating activities: Share-based compensation expense 3,315 5,385 Depreciation expense 84 2,155 Non-cash interest expense 5,587 5,339 Inventory fair value step-up adjustment included in cost of product sales 850 1,186 Amortization of intangible assets 1,164 259 Loss on change in fair value of contingent value rights 395 - Amortization of right-of-use lease assets 169 1,091 Loss on short-term investments - 502 Loss on disposal of property and equipment, net of gain on lease termination - 59 Changes in operating assets and liabilities: Accounts receivable, net (2,959 ) 218 Inventory, net (931 ) (1,482 ) Prepaid expenses and other current assets (875 ) 2,445 Accounts payable (448 ) (1,649 ) Accrued expenses 4,083 (5,786 ) Accrued payroll and related expenses (1,077 ) (2,168 ) Lease liabilities (168 ) (1,969 ) Net cash provided by (used for) operating activities 25,080 (30,358 ) Investing activities Acquisition of Tetraphase, net of cash, cash equivalents and restricted cash acquired - (33,513 ) Proceeds from the sale of property and equipment - 3,070 Purchases of property and equipment (9 ) - Proceeds from the sale of short-term investments - 2,497 Purchases of short-term investments - (2,999 ) Net cash used for investing activities (9 ) (30,945 ) Financing activities Net proceeds from issuance of common stock under ESPP 317 428 Net proceeds from issuance of common stock under 2013 Equity Plan 156 605 Net cash provided by financing activities 473 1,033 Net increase (decrease) in cash, cash equivalents and restricted cash 25,544 (60,270 ) Cash, cash equivalents and restricted cash, beginning of period 21,261 88,729 Cash, cash equivalents and restricted cash, end of period $ 46,805 $ 28,459 Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets Cash and cash equivalents $ 46,765 $ 27,760 Restricted cash 40 699 Total cash, cash equivalents and restricted cash $ 46,805 $ 28,459

机构